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Abstract
OBJECTIVES: Transcatheter aortic valve implantation (TAVI) is an alternative to surgery for high-risk patients with severe aortic valve
stenosis. Periprocedural stroke is reported at an incidence up to 10%. Magnetic resonance imaging studies have identiﬁed new onset of
clinically silent ischaemic cerebral lesions more frequently (68–84%). So far, few data are available about cerebral embolism during
TAVI. The aim of this study was to determine the frequency of high-intensity transient signals (HITS) and to explore differences in the
HITS pattern between transfemoral and transapical access and between self-expanding (SE) and balloon-expandable (BE) deployment
technique.
METHODS: Transcranial Doppler (TCD) ultrasound recordings of 44 patients undergoing TAVI (age 78 ± 6 years; logistic EuroSCORE
28 ± 15%; transfemoral access, n = 32; transapical access, n = 12; SE, n = 27; BE, n = 17) were analysed for HITS during the following
intervals: (i) instrumentation prior to valvuloplasty, (ii) balloon valvuloplasty, (iii) prosthesis deployment (DP) and (iv) post-implant-
ation (PI) including any re-dilatation episodes. The total procedural load of HITS and HITS frequency in procedural intervals were
compared between different access routes and DP techniques. Periprocedural neurocognitive impairment was assessed clinically
and by the confusion assessment method (CAM) prior to TAVI and on post-procedural days 1 and 4–6.
RESULTS: TCD recordings demonstrated the occurrence of HITS in all patients. DP was associated with the highest load of HITS.
Access route did not signiﬁcantly inﬂuence the total burden of periprocedural HITS. During procedures using the SE type, a slightly
larger total load of HITS was observed than with the BE type (P = 0.024). This was mainly due to more HITS during the DP (P =
0.027) and the PI interval (P = 0.002). No incidence of delirium was detected by CAM ratings. Two patients suffered a new onset of
stroke within the 2 weeks following the procedure. In-hospital death and 30-day mortality were 0/44.
CONCLUSIONS: HITS are observed during all procedural intervals in TAVI. The embolic events appear to peak during DP. In our
series, the overall cerebral embolic load did not differ between the transfemoral and the transapical access route. TCD monitoring
in TAVI is useful to identify periods and manipulations associated with an increased cerebral embolic load and may help to further
enhance the safety of this procedure.
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INTRODUCTION
Since the ﬁrst case report by Cribier, transcatheter aortic valve
implantation (TAVI) has emerged as a treatment option for
elderly patients with severe valvular aortic stenosis deemed at
high risk for conventional surgery [1, 2]. Although TAVI has been
shown to decrease mortality and improve the quality of life in
selected high-risk patients who are not suitable candidates for
surgical aortic valve replacement (SAVR), the transcatheter
method involves interventional techniques with a higher degree
of invasiveness than simple cardiac catheterization [3, 4]. During
cardiac catheterization and accompanying manoeuvres,
however, studies have reported both clinically apparent and
silent brain embolism by the disruption of vascular plaques and/
or calciﬁc debris of the aortic valve [5, 6].
TAVI requires even more extensive intravascular use of guide
wires and catheters [4, 7]. In selected cases, concomitant coron-
ary, intracardiac or carotid interventions become necessary due
to patients’ co-morbidities or intraprocedural complications.
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Also, the population undergoing TAVI consists of patients of
advanced age with a high prevalence of aortic atheromatosis.
Therefore, cerebral embolization during TAVI might be even
more frequent than during cardiac catheterization alone.
The incidence of periprocedural stroke during TAVI is similar
to that reported in conventionally operated patients with aortic
stenosis and rates vary widely (3.8–10%; P. Wenaweser et al., sub-
mitted for publication) [8–10]. Clinically silent new ischaemic
brain lesions have been reported to occur even more frequently
(68–84%), as observed in recent diffusion-weighted cerebral
magnetic resonance imaging (DW-MRI) studies [11–14].
In order to develop strategies for reducing the risk of cerebral
embolism during TAVI, the recognition of cerebral embolic
events and their relationship with procedural intervals would be
desirable. For this purpose, transcranial Doppler (TCD) ultra-
sound is commended monitoring modality to detect and quan-
tify, non-invasively and in real-time, high-intensity transient
signals (HITS), which represent solid or gaseous cerebral micro-
emboli passing the middle cerebral artery (MCA) [15, 16].
The aim of this study was to measure the quantity of HITS
during TAVI and to relate it to different procedural intervals,
deployment techniques of the aortic bioprosthesis, access routes
and early post-procedural neurological outcome.
MATERIALS AND METHODS
Patients
During the study period, a total of 67 consecutive patients
underwent TAVI at our institution and were followed prospect-
ively within an institutional registry. Patients were considered for
TAVI if they had severe symptomatic aortic valve stenosis with a
calculated aortic valve area <1 cm2 or an aortic valve mean pres-
sure gradient of >40 mmHg on echocardiography, age ≥ 80 years
and/or a logistic EuroSCORE ≥ 15%, or age > 70 years with a pre-
dicted high or prohibitive risk of morbidity or/and mortality for
SAVR. Patient selection, indication for TAVI and contraindications
for SAVR were reviewed and had to be agreed upon by a con-
sensus team of interventional cardiologists and cardiac surgeons.
Registry data and TCD recordings were collected in a pro-
spective observational fashion, without any study intervention,
and were analysed with written informed consent of the patients
and the approval of the Institutional Review Board.
Transcatheter aortic valve implantation
procedure
Depending on anatomical conditions, feasible access sites and
indications for aortic bioprosthesis type and size, either the
transfemoral, the transapical or the trans-subclavian access was
chosen. All procedures were performed as reported previously
in detail by our group and others [4, 7]. General endotracheal
anaesthesia using a total intravenous technique (propofol com-
bined with remifentanil) was administered in all transapical and
trans-subclavian access TAVI. In transfemoral TAVI (TF-AVI), local
anaesthesia with monitored anaesthesia care was chosen for the
majority of cases, using a sedative and analgesic combination of
propofol and racemic ketamine. Continuous anaesthesia moni-
toring consisted of ECG, pulse oximetry, capnography, invasive
arterial and central venous pressure as well as TCD. Either the
balloon-expandable (BE) Edwards SAPIEN valve (Edwards
Lifesciences Inc., Irvine, CA, USA) or the self-expanding (SE) Core
Valve Revalving system (Medtronic Inc., Minneapolis, MN, USA)
was implanted.
The periprocedural antithrombotic regimen consisted of
intravenous administration of a weight adjusted bolus of heparin
(70–100 IU/kg) in order to achieve an activating clotting time of
>250 s for the duration of the procedure. The antiplatelet
regimen consisted of acetylsalicylic acid of 100 mg and a loading
dose of 300 mg clopidogrel in TF-AVI patients on the day prior
to the procedure. For patients undergoing transapical TAVI
(TA-AVI), the clopidogrel loading dose was administered 6 h after
apical access closure. Patients were discharged with the prescrip-
tion of acetylsalicylic acid 100 mg/day indeﬁnitely and clopido-
grel 75 mg/day for 3–6 months. In the case of an indication for
oral anticoagulation, warfarin was combined with either acetyl-
salicylic acid or clopidogrel alone.
Transcranial Doppler ultrasonography
and embolus detection
As part of the institutional practice in cerebral monitoring prior
to and during TAVI, a TCD probe (2 MHz pulsed-wave trans-
ducer; Spencer Technologies, Seattle, WA, USA) was placed bilat-
erally at the temporal bone acoustic window. A commercially
available probe-holding head frame system for continuous HITS
acquisition (Marc 600 series; Spencer Technologies) was used.
Power output and gain settings were adjusted on the TCD
machine (ST3, Model # PMD150; Spencer Technologies) to
provide an optimal signal-to-noise ratio. The sample volume was
3–6 mm3. Using the 33 gate Power M-mode™ function for rapid
vessel localization, characteristic blood ﬂow velocity spectra were
easily detected with high signal quality by insonation of the
MCA at a depth between 48 and 56 mm.
HITS detection was performed automatically using the multi-
depth embolic detection with artefact rejection. Because certain
technical criteria must be met to qualify HITS as microemboli, all
TCD recordings were reviewed (G.E.) in a blinded fashion after
the procedures to conﬁrm the quantity and the quality of micro-
embolic signals [17]. Thereafter, TCD recordings were analysed
according to the deﬁned protocol. The cumulative counts of
HITS recordable during the period between establishment and
closure of vascular access were analysed, as well as the load of
HITS accumulated during the following procedural intervals: (i)
instrumentation prior to balloon valvuloplasty of the native aortic
valve (IN), deﬁned as the period from ﬁrst femoral vessel punc-
ture until the transcatheter introduction of the valvuloplasty
balloon; (ii) balloon valvuloplasty of the native aortic valve (BV),
deﬁned as the period from the transcatheter introduction of the
valvuloplasty balloon until the transcatheter introduction of the
balloon-mounted valve; (iii) prosthesis deployment (DP), deﬁned
as the period from the transcatheter introduction of the balloon-
mounted valve until the removal of the deployment system and
(iv) the post-implantation (PI) phase, deﬁned as the period from
the removal of the valve deployment system until the closure of
the access, also including any re-dilatation episodes. The duration
of each interval was recorded in the interventional protocols and
was used to calculate the average rate of HITS per minute for
each interval.
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Neurologic and neurocognitive assessment
A gross clinical neurologic status was documented 1 day prior to
TAVI and after TAVI at days 1–6 by the attending anaesthesiologist.
Patients were screened for stroke and post-procedural delirium
by the confusion assessment method (CAM), which was applied
prior to TAVI and on post-procedural days 1 and 4–6 [18]. As per
institutional policy, any pathological ﬁnding at clinical examin-
ation or CAM had to be veriﬁed by a neurology consultant, and if
appropriate, neuroimaging studies were performed.
Statistical analysis
Categorical data are given as numbers and percentages and
were compared using the chi-squared or Fisher’s exact test
where appropriate. Continuous data are described using
medians with interquartile ranges; for comparisons between
groups (deployment technique and access route) or repeated
measures (procedural intervals), a non-normal distribution was
assumed, and non-parametric testing was applied (Mann–
Whitney rank-sum test; Friedman repeated-measures ANOVA on
ranks). A P-value of <0.05 was considered as statistically signiﬁ-
cant. Statistical analyses were performed using Sigma Plot for
Windows, Version 10.0, and Sigma Stat for Windows, Version 3.0
(Systat Software, Inc., Germany).
RESULTS
Demographics of the study population
and procedure characteristics
Of 67 consecutive TAVI procedures in the observation period, 44
patients (66%) exhibited MCA spectra of good quality through-
out the whole TAVI procedure and were included in the study. In
the remaining 23 patients (34%), either no TCD could be per-
formed for logistic reasons or MCA signals were inconsistently or
not obtained due to the absence of an acoustic window, prohi-
biting continuous bilateral TCD recording and HITS detection
throughout the procedure. Thus, these patients were excluded.
The TAVI access route was transfemoral in 32 patients, and
transapical in 12 patients. In the majority of the cases, an SE
prosthesis type was implanted (n = 27). In contrast to SE pros-
theses, BE prostheses were implanted both transfemorally (n = 5)
and transapically (n = 12).
Baseline characteristics of the study population are shown in
Table 1. Procedural characteristics are given in Table 2 and dem-
onstrate, in TA-AVI procedures, a signiﬁcantly longer duration of
IN than in TF-AVI procedures (P = 0.01). There were, however, no
other signiﬁcant differences between time requirements (overall
procedure duration: TF-AVI, 67 min vs. TA-AVI, 83 min; P = 0.7).
In both groups, the longest procedural interval was IN.
High-intensity transient signal-derived cerebral
embolic load and neurologic performance
Counts of HITS were symmetrically distributed between left
and right MCA territories. Symmetry of hemispheric distribution
was independent from the procedural period, access route and
deployment technique (Table 3).
The total procedural load of HITS did not differ signiﬁcantly
between access routes, but was smaller in BE-type than in
SE-type prostheses [BE, 412 (354–585); SE, 580 (456–777 );
P = 0.024; Table 4].
For both access routes and prosthesis types, the largest
embolic load occurred during the few minutes of DP. In particu-
lar, SE-type prostheses released more HITS than BE-type valves
during this interval [SE, 256 (132–352); BE, 158 (103–201); P =
0.027; Table 4].
During instrumentation, a relatively large embolic load
occurred, too (Table 4). This interval lasted, however, more
than half an hour, i.e. much longer than the deployment
interval. The access type and the deployment technique did
not exhibit differences in HITS during the instrumentation
period.
Table 2: Procedural characteristics
All TAVI TF-AVI TA-AVI P-value
n 44 32 12
Overall duration (min)a 75 ± 18 67 ± 16 83 ± 22 0.7
Duration (min)b
Instrumentation (IN) 36 (17–58) 30 (23–40) 43 (39–52) 0.01
Valvuloplasty (BV) 3 (2–6) 4 (2–5) 3 (3–3.5) 0.4
Deployment (DP) 2 (1–5) 2 (2–3) 2 (2–2.5) 0.6
Post-implantation 26 (15–60) 26 (20–36) 26 (16–50) 0.9
TAVI: transcatheter aortic valve implantation; TF-AVI: transfemoral
aortic valve implantation; TA-AVI: transapical aortic valve
implantation.
aValues are the mean ± SD.
bValues are the median (25th; 75th percentile).
Table 1: Baseline characteristics of the study population
All TAVI TF-AVI TA-AVI
n 44 32 12
Age (years)a 78 ± 6 79 ± 5 74 ± 8
Male sexb 24 (55) 17 (53) 8 (67)
NYHA classc III (III; III) III (III; III) III (III; III)
Log EuroSCORE (%)a 28 ± 15 29 ± 17 25 ± 10
LV-EF (%)a 48 ± 17 46 ± 16 55 ± 18
Valve area (cm2)a 0.6 ± 0.2 0.7 ± 0.2 0.6 ± 0.2
History of atrial fibrillationb 3 (7) 3 (9) 0 (0)
Coronary artery diseaseb 27 (61) 19 (59) 8 (67)
History of strokeb 1 (2) 1 (3) 0 (0)
ICA stenosis >50%b 7 (16) 6 (19) 1 (8)
NYHA: New York Health Association class; Log EuroSCORE: European
System for Cardiac Operative Risk Evaluation Score; LV-EF: left
ventricular ejection fraction; ICA: internal carotid artery; TAVI:
transcatheter aortic valve implantation; TF-AVI: transfemoral aortic
valve implantation; TA-AVI: transapical aortic valve implantation.
aValues are the mean ± SD.
bValues are n (%).
cValues are the median (25th; 75th percentiles).
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In the PI interval, transfemoral implants generated more HITS
compared with transapical implants [TF-AVI, 63 (44–124); TA-AVI,
30 (13–49); P = 0.004; Table 4). Also, the deployment technique
had a small inﬂuence on PI HITS [SE, 71 (44–125); BE, 32 (18–
49); P = 0.02; Table 4). Figure 1 summarizes the relevant results.
There was no incidence of delirium (as measured by CAM)
during hospital stay; however, one patient of the TF-AVI group
and one patient of the TA-AVI group suffered new stroke on the
post-interventional days 4 and 13, respectively. No in-hospital
death occurred, and the 30-day mortality was 0/44 in the entire
cohort.
DISCUSSION
In patients undergoing TAVI, we determined the quantity and
the distribution of HITS by TCD ultrasound. We related the
occurrence of HITS to procedural intervals, types of vascular
access and deployment techniques.
The main ﬁnding is that the peak HITS load occurs during the
very short interval of valve deployment. Pre-implantation instru-
mentation releases almost as many HITS, although over a longer
time period. The other intervals are characterized by both
shorter duration and lower incidence of HITS. Our main results
are in good accordance with a recent TCD study performed
exclusively in TA-AVI procedures, where microembolic signals
were detected in all patients and where peak embolic frequency
was also recorded during valve delivery [19].
Additional ﬁndings of our study describe the effect of access
route and deployment technique on the incidence of HITS: a
larger total load of HITS was observed with the use of SE
Figure 1: HITS load according to the TAVI access route and the deployment
technique.
Table 3: Total, left and right hemispheric HITS counts in relation to procedural intervals
Period and access Total HITS HITS left MCA HITS right MCA aP-value
All TAVI (n = 44)
Overall 548 (386–692) 255 (190–354) 274 (185–356) 0.93
Instrumentation (IN) 137 (102–190)* 73 (47–94) 73 (50–103) 0.90
Valvuloplasty (BV) 63 (32–109) 32 (17–52) 29 (12–54) 0.38
Deployment (DP) 183 (112–316)* 93 (48–157) 98 (53–142) 0.63
Post-implantation 50 (22–97) 28 (12–47) 23 (10–45) 0.07
Values are the median (25th; 75th percentile). TAVI: transcatheter aortic valve implantation; HITS: high-intensity transient signal; MCA: middle cerebral
artery.
aComparison between left and right MCA.
*P < 0.05 vs. BV, PI.
Table 4: The HITS load per procedural interval
depending on the deployment technique and the access
route
Deployment technique SE (n = 27) BE (n = 17) P-value
HITS total procedure 580 (456–777) 412 (354–585) 0.024
Instrumentation 155 (102–194) 136 (93–197) 0.66
Valvuloplasty 64 (41–97) 46 (12–161) 0.46
Deployment 256 (132–352) 158 (103–201) 0.027
Post-implantation 71 (44–125) 32 (18–49) 0.002
Access route TF (n = 32) TA (n = 12) P-value
HITS total procedure 563 (393–731) 428 (370–664) 0.22
Instrumentation 156 (103–203) 121 (56–152) 0.16
Valvuloplasty 62 (32–95) 72 (30–188) 0.47
Deployment 198 (111–431) 178 (137–207) 0.40
Post-implantation 63 (44–124) 30 (13–49) 0.004
Values are the median (25th; 75th percentile). HITS: high-intensity
transient signal; SE: self-expanding deployment technique; BE:
balloon-expandable deployment technique; TF: transfemoral access
route; TA: transapical access route.
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prostheses. This difference was attributable to more HITS during
both DP and PI. Several hypotheses may be discussed to explain
these observations: counts of HITS during instrumentation,
balloon valvuloplasty, deployment and total procedure were
found to be quite similar in transfemoral and transapical
approaches. Although the transapical access is associated with
less catheter trafﬁc through ascending aorta and aortic arch, this
appears to have less impact on the embolic load than the inter-
action of rigid wires and stent/frame structures with aortic valvu-
lar and root calciﬁcations. The interaction between hardware
and aortic root calciﬁcations may become aggravated by the
speciﬁc deployment technique of the SE-type prosthesis. In our
series, SE-type valves were exclusively released without rapid
right ventricular pacing. Thus, antegrade ejection continued
during most of the gradual release process of the framed valve.
This may lead to prolonged friction between prosthetic frame
and calciﬁcations, and the antegrade embolization of debris may
be promoted by sustained cardiac ejection. In this regard, stop-
ping ejection brieﬂy by rapid pacing, until the frame is seated,
may even be protective for the brain. At the present stage,
however, these considerations still remain theoretical and
require further study.
Further, there was the ﬁnding of a low HITS rate during PI,
which was nevertheless slightly higher with transfemoral access
and SE deployment technique. More frequent re-dilation man-
oeuvres of deployed but regurgitant TF/SE prostheses may have
played a role [the number of patients with re-dilatation: SE = 5
(18%) vs. BE = 1 (6%)]. Also, the removal of large-bore transfe-
moral introducers through the aortic arch may have led to the
contact with and friction at atheromatous wall areas upstream of
cephalic branch vessels.
Given the lack of other TCD studies comparing the transfe-
moral with the transapical access route in TAVI, discussions of
pathomechanism must rely on studies into micro-embolization
during cardiac catheterization [20, 21]. These reports also em-
phasize the potentially harmful consequences of stiff large-bore
catheters and of ﬂushing and contrast injection in the athero-
sclerotic ascending aorta and the higher risk of cerebral embol-
ization in patients with coronary artery disease.
At present, the clinical signiﬁcance of the observed incidence
and periprocedural distribution of HITS remains unclear. Despite
reliable and objective TCD recordings, as shown by the symmet-
rical distribution of HITS between brain hemispheres, we found
no clinically apparent differences in the gross periprocedural
neurocognitive outcome to associate them with the HITS load,
deployment technique or access route. Likewise, the strokes
detected in two patients in the post-procedural phase were not
associated with increased counts of HITS during TAVI, which
reﬂects multifactority and complexity of cerebral ischaemic
events. With low event rates of new-onset stroke (4%), delirium
and in-hospital death (0% each), this study was not powered to
detect associations between the HITS load and these major
adverse clinical outcomes.
Our results are in agreement with previously published
neuroimaging studies prior to and after TAVI (Table 5). In a series
investigating both the transfemoral and the transapical valve
implantation technique, 68% of the treated patients had new
cerebral ischaemic lesions on DW-MRI post-interventionally,
even though a clinical neurological correlate was detected in
only 3.3%. Similarly, other reports, which exclusively studied
TF-AVI or TA-AVI, conﬁrmed a periprocedural incidence of per-
manent neurological impairment in the range of 3.6–5%, with a
15–20× higher rate of clinically silent new ischaemic foci on
DW-MRI [11–14].
To date, no consensus exists on the clinical impact of HITS,
although evidence is accumulating that cerebral embolism plays
a contributing role in the pathogenesis of post-operative cogni-
tive decline [22–24]. In patients undergoing coronary artery
bypass surgery, the overall number of HITS has been found to
correlate with changes in cerebral activity at functional MRI [25].
This study has several limitations besides its non-randomized
design, small cohort size and lack of power for low-incidence
outcomes. Neurocognitive assessment was based on clinical
neurological examination and CAM only. The subgroups deﬁned
by the access route and the deployment technique were of
imbalanced size; they were also not independent categories,
since the SE-type prosthesis was implanted exclusively by the
transfemoral route. In addition, the less number of TF-AVI cases
in the BE group limits any statistical comparison between the
two prosthesis types with regard to the implantation technique.
It is thus not yet possible to discriminate the causative role of
access and the deployment type for HITS release. Also, proced-
ural techniques may vary between interventionists and institu-
tions; transferability of its results to different institutional settings
or patient populations may therefore be limited. Nevertheless,
our study conﬁrms procedure-related cerebral embolism during
TAVI. As a portable non-invasive cerebral monitoring device,
TCD provides the real-time detection of HITS in TAVI patients
[15, 16]. Insonation of the MCA permits accurate monitoring of
70% of the total cerebral blood ﬂow and therefore the detection
of a majority of cerebral embolic events. Nevertheless, the speci-
ﬁcity of HITS detection for clinically apparent embolic stroke is
necessarily low, and embolic stroke can also occur post-
procedurally after the removal of the TCD monitor.
Table 5: Current neuroimaging studies in TAVI
Author Year Patients (n) TAVI type Neuroimaging modality Silent new lesion (%) New-onset stroke (%)
Drews [19] 2011 50 TA-AVI CT 8 0
Rodes-Cabau [11] 2011 60 TF/TA-AVI DW-MRI 68 3.3
Kahlert [12] 2010 32 TF-AVI DW-MRI 84 5
Ghanem [13] 2010 22 TF-AVI DW-MRI 72.7 3.6
Arnold [14] 2010 25 TA-AVI DW-MRI 68 4
TAVI: transcatheter aortic valve implantation; TF-AVI: transfemoral aortic valve implantation; TA-AVI: transapical aortic valve implantation; CT: computed
tomography; DW-MRI: diffusion-weighted magnetic resonance imaging.
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In conclusion, TCD-detectable cerebral embolism occurs regu-
larly during TAVI. We observed statistical associations of the
embolic event rate with deployment techniques and deﬁned
procedural phases; speciﬁcally, the event rate peaks during valve
deployment. Our ﬁndings are so far derived from a patient
cohort of a size yet to small to allow for robust conclusions.
Nevertheless, this study has demonstrated that TCD monitoring
in TAVI helps to identify periods and manipulations associated
with increased cerebral embolic risk and points out areas for
further technical improvement.
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APPENDIX. CONFERENCE DISCUSSION
Dr J. Seeburger (Leipzig, Germany): There is actually only one thing I would
like to ask. When it comes to stroke, it seems that the technology of transcra-
nial Doppler is becoming an issue. So far, you have only shown that this is
feasible, that you can detect any embolic growth that you see during TAVI,
but has it ever changed the management of such a procedure? So the ques-
tion I would like to ask is, how do you think you can improve and what is the
relevance behind the study other than descriptive? How do you think you
can change the management of TAVI using the method that you just
presented?
Dr Huber (Bern, Switzerland): There are new device types on the horizon,
cerebral embolic protection devices. The questions now are, should these be
used routinely or not, in what phases of the intervention should they be
used, and what do we do with all the late strokes after the intervention? The
other question is, is there a relationship between the device and the stroke
rate? I think, as a very ﬁrst step, transcranial Doppler might be used to help
answer such questions. Obviously the results should be related to MRI
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ﬁndings as well, and also to improved and in-depth neurologic examination
in the long run during the follow-up period.
The deployment process might be of particular interest. We have observed
that patients having self-expanding devices all had implantation without rapid
pacing. Therefore it might be of importance to have rapid pacing in order to
decrease blood ﬂow through the aortic valve during device implantation.
That might be one of the results of this paper that we want to have a look at
in the future.
Dr L.K. von Segesser (Lausanne, Switzerland): I have a question. Throughout
your presentation you have used the term “HITS” for high-intensity signals
and emboli, sometimes quite ambivalently, and I think we have to state that
these are not the same: high-intensity signals are signals but they are not ne-
cessarily emboli. A typical example, for instance, is that when you test for
patency of the foramen ovale with some bubbles, there are signals. You can
detect them with the Doppler, but they are not considered emboli but are
injected on purpose. Please comment.
Dr Huber: Those are types of gaseous emboli, gas bubbles, that will travel
with the blood ﬂow somewhere into an end organ in the patient’s body. It is
not certain whether they cause any harm. But you are right, we should be
careful about the distinction between the word “HITS” and the word
“emboli”, as emboli might relate more to something that has a signiﬁcant
clinical impact, as opposed to HITS that might just be turbulence of ﬂow. But
the entire transcranial Doppler study has been reviewed by the same oper-
ator on all patients to try to exactly identify all the artefacts in the signals that
we are measuring.
Dr N.M. Van Mieghem (Rotterdam, The Netherlands): Christoph, I have a
question regarding transcranial Doppler. We have also been using this
technology, and we went nuts because we had HITS all the time during the
procedure that we could not interpret. So I am wondering, have you
evaluated the interobserver and intraobserver variability? And the person
who is performing the measurements, is he doing simultaneous Doppler
measurements on the left and right carotid, and using his two hands
during the procedure?
Dr Huber: First of all, there is no interoperator variability because the
person who did all the measurements was always the same, Erdos Gabor, our
anaesthetist. The transcranial Doppler is placed on both sides of the patient,
so that there is simultaneous recording. But you are right, it is very difﬁcult
because, for example, initial manipulation at the apex starts to generate HIT
signals, and I am really not sure why this should happen when still working
on the outside of the heart. We certainly saw differences in procedural steps,
and intuitively you would have expected those different steps to have a
higher HITS burden, and that is exactly what we found. I think the informa-
tion is quite accurate and interesting, even though the patient numbers are
low.
Dr F. Maisano (Milan, Italy): I understood from your data that the self-
expanding devices have a slightly higher amount of HITS. Do you think that
this is due to the higher number of patients having post-dilatation?
Dr Huber: In regards to the access route, this is rather a discussion point; the
post-implantation interval was the only one with a signiﬁcant difference. The
same difference is again shown in the type of deployment. In the post-
implantation phase, one reason for increased HITS might be because of more
post-deployment dilatation accounting for ﬁve in the self-expanding group and
only one in the balloon-expanding group. Obviously this could also be with-
drawal of the delivery system scratching the aortic arch, for example; we haven’t
really sub-analysed the whole phase, but we thought this could have been the
reason, although there is no way we can prove this for the time being.
Dr Maisano: The way that HITS are generated in the two systems can be
quite different. In a self-expanding device you have the unsheathing process,
which is opening the door to air embolism when you unsheath the device
which has been prepared outside of the body, while with balloon-expandable
devices you don’t have this mechanism. Can you discuss this a little bit?
Dr Huber: Well, that certainly also might be an impacting factor. I am
pretty sure that everybody using self-expanding devices makes certain that
they are well de-aired and that there are no air bubbles, but, if there were, it
would certainly impact. However, I think, rather, that the implantation time of
a self-expanding device ﬁrst of all is much longer. There is this kind of device
friction to the aortic wall, that is being generated all along during implant-
ation with a heart that continues to beat and has ejection, and I think it is
during that process that most HITS will be generated, and I think this is what
requires detailed analysis.
Dr T. Drews (Berlin, Germany): I think it is very important to show the rate
of embolism during this procedure. Therefore at the beginning of this year
we published a paper on transapical Doppler results during transapical valve
implantation, and we also found that during valvuloplasty and valve delivery
we had the highest rates of microembolism and HITS. I have two questions.
At ﬁrst, we discovered that one-third of patients had a history of stroke
before the valve device has been implanted. We found this by computer
tomography. Do you have some results from preoperative data? And the
second question is, you mentioned self-expanding valves. The CoreValve is
self-expanding. Do you have any data on HITS or microembolism from
patients treated by retrieval of the partially deployed prosthesis through the
aorta and the introducer sheath and reimplantation of the same prosthesis?
Dr Huber: Regarding your ﬁrst question, it actually wasn’t the aim of the
study to relate to stroke, so we haven’t speciﬁcally analysed for strokes in
these patients. The aim was to see which procedural step would generate
most HITS. As to your second question, no, we haven’t had any patient where
we had to reposition the self-expanding device in the subset of the popula-
tion we have included.
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